Translational research on novel drug-eluting stents in percutaneous coronary intervention

Frontiers of Medicine in China

Volumn 5, Issue 4, 2011, Pages 395-400

  Han, Yaling ^a   Xu, Kai ^a   Yan, Chenghui ^a  

^a GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

Author keywords

drug eluting stents; percutaneous coronary intervention; translational research

Indexed keywords

CORONARY ARTERY DISEASE; DRUG ELUTING STENT; HUMAN; METHODOLOGY; REVIEW; THROMBOSIS; TRANSLATIONAL RESEARCH; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, BALLOON, CORONARY; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; HUMANS; THROMBOSIS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84255188519     PISSN: 16737342     EISSN: 16737458     Source Type: Journal    
DOI: 10.1007/s11684-011-0167-1     Document Type: Review

References (20)

1. McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T, Suddath WO, Weissman NJ, Torguson R, Kent KM, Pichard AD, Satler LF, Waksman R, Serruys PW. Late thrombosis in drugeluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004; 364(9444): 1519-1521.
2. Kotani J, Awata M, Nanto S, Uematsu M, Oshima F, Minamiguchi H, Mintz GS, Nagata S. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol 2006; 47(10): 2108-2111.
3. Nakazawa G, Otsuka F, Nakano M, Vorpahl M, Yazdani SK, Ladich E, Kolodgie FD, Finn AV, Virmani R. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol 2011; 57(11): 1314-1322.
4. Windecker S. Stent thrombosis: evidence from clinical trials. European Society of Cardiology Congress 2011. 27-31 August, 2011. Paris, France.
5. Wessely R. New drug-eluting stent concepts. Nat Rev Cardiol 2010; 7(4): 194-203.
6. Jaschke B, Michaelis C, Milz S, Vogeser M, Mund T, Hengst L, Kastrati A, Schömig A, Wessely R. Local statin therapy differentially interferes with smooth muscle and endothelial cell proliferation and reduces neointima on a drug-eluting stent platform. Cardiovasc Res 2005; 68(3): 483-492.
7. Lewis AL, Willis SL, Small SA, Hunt SR, O'byrne V, Stratford PW. Drug loading and elution from a phosphorylcholine polymer-coated coronary stent does not affect long-term stability of the coating in vivo. Biomed Mater Eng 2004; 14(4): 355-370.
8. Jaschke B, Milz S, Vogeser M, Michaelis C, Vorpahl M, Schömig A, Kastrati A, Wessely R. Local cyclin-dependent kinase inhibition by flavopiridol inhibits coronary artery smooth muscle cell proliferation and migration: Implications for the applicability on drug-eluting stents to prevent neointima formation following vascular injury. FASEB J 2004; 18(11): 1285-1287.
9. Kim W, Jeong MH, Cha KS, Hyun DW, Hur SH, Kim KB, Hong YJ, Park HW, Kim JH, Ahn YK, Kim MH, Cho JG, Park JT, Park JC, Kang JC. Effect of anti-oxidant (carvedilol and probucol) loaded stents in a porcine coronary restenosis model. Circ J 2005; 69(1): 101-106.
10. Han Y, Li Y, Wang S, Jing Q, Wang Z, Wang D, Shu Q, Tang X. Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. Am Heart J 2009; 157(4): 733-739.
11. Lee CW, Park DW, Seung KB, Kim PJ, Park HJ, Kim WJ, Lee JY, Kang SJ, Lee SH, Kim YH, Park SW, Park SJ. Comparison of dual drug-eluting Cilotax stent and paclitaxel-eluting Taxus Liberte stent in native coronary artery lesions. Am J Cardiol 2011; 107(7): 990-994.
12. Suzuki Y, Yeung AC, Ikeno F. The pre-clinical animal model in the translational research of interventional cardiology. JACC Cardiovasc Interv 2009; 2(5): 373-383.
13. Schwartz RS, Edelman ER; For the Consensus Committee: Carter A, Chronos N, Rogers C, Robinson KA, Waksman R, Weinberger J, Wilensky RL, Jensen DN, Zuckerman BD, Virmani R. Drug-eluting stents in preclinical studies: recommended evaluation from a consensus group. Circulation 2002; 106(14): 1867-1873.
14. Abizaid A, Costa JR Jr. New drug-eluting stents: an overview on biodegradable and polymer-free next-generation stent systems. Circ Cardiovasc Interv 2010; 3(4): 384-393.
15. Serruys PW, Onuma Y, Ormiston JA, de Bruyne B, Regar E, Dudek D, Thuesen L, Smits PC, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Miquel-Hebert K, Rapoza R, García-García HM. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Circulation 2010; 122(22): 2301-2312.
16. Tanimoto S, Serruys PW, Thuesen L, Dudek D, de Bruyne B, Chevalier B, Ormiston JA. Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the everolimus-eluting cobalt chromium coronary stent: insights from the ABSORB and SPIRIT trials. Catheter Cardiovasc Interv 2007; 70(4): 515-523.
17. San Juan A, Bala M, Hlawaty H, Portes P, Vranckx R, Feldman LJ, Letourneur D. Development of a functionalized polymer for stent coating in the arterial delivery of small interfering RNA. Biomacromolecules 2009; 10(11): 3074-3080.
18. Han Y, Guo L, Yan C, Guo P, Deng J, Mai X, Kang J, Li S. Adenovirus-mediated intra-arterial delivery of cellular repressor of E1A-stimulated genes inhibits neointima formation in rabbits after balloon injury. J Vasc Surg 2008; 48(1): 201-209.
19. Fishbein I, Alferiev I, Bakay M, Stachelek SJ, Sobolewski P, Lai M, Choi H, Chen IW, Levy RJ. Local delivery of gene vectors from bare-metal stents by use of a biodegradable synthetic complex inhibits in-stent restenosis in rat carotid arteries. Circulation 2008; 117(16): 2096-2103.
20. Bonta PI, Pols TW, van Tiel CM, Vos M, Arkenbout EK, Rohlena J, Koch KT, de Maat MP, Tanck MW, de Winter RJ, Pannekoek H, Biessen EA, Bot I, de Vries CJ. Nuclear receptor Nurr1 is expressed in and is associated with human restenosis and inhibits vascular lesion formation in mice involving inhibition of smooth muscle cell proliferation and inflammation. Circulation 2010; 121(18): 2023-2032.